109 results
Page 2 of 6
6-K
EX-99.2
3ap 4t6qx5i
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
nbp1t bg7swd43i
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
itr8o5r f79
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
od2gfc c5z25k16ep
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
solcph11s77lmtuv
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
yzg4k512
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
1waetwo o7i39oa
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
d0vkiox skqgm
10 May 23
Current report (foreign)
7:27am
6-K
j2td mfiv
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
1dg02zx
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
rt7 ccpaxm
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
7iwpz2w0q uunqf
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
czpmok
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
jgh 17joul5czd
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.1
hfnywl14vbbd y4brsv
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.4
rbirnzzbxbw20ow
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
92lx527ox6dj0q
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
3q5 3qxtb3u9k7b
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-1.1
1zfdfeau 0scs
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
22patm5
9 Sep 22
Prospectus supplement for primary offering
4:23pm